| Code | CSB-RA004894MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar of siplizumab (MEDI-507/TCD601), targeting CD2 (also known as LFA-2)—a surface glycoprotein of the immunoglobulin superfamily expressed primarily on T cells and NK cells. CD2 mediates tight cell–cell interactions through binding to CD58 (LFA-3) on antigen-presenting and other immune cells, providing an adhesion and costimulatory axis that can lower activation thresholds and shape T-cell functional responses.
Siplizumab is described as a non-agonistic, humanized IgG1 anti-CD2 monoclonal antibody developed to modulate immune activity by targeting CD2-positive lymphocytes. As an Fc-active anti-CD2, it has been studied for its ability to deplete CD2⁺ T and NK cells via Fc-effector mechanisms (and has been reported to induce NK-cell fratricide in mechanistic studies), enabling controlled interrogation of depletion biology versus pure costimulation blockade. This biosimilar supports research into CD2/CD58 pathway biology, immune-synapse signaling, and Fc-dependent immunomodulation in assay development and translational immunology models (e.g., GVHD or immune-mediated inflammation studies).
There are currently no reviews for this product.